drugset / Trial / NCT00798915
Study of the Effects of Xenin-25 in Humans With and Without Type 2 Diabetes Mellitus
Phase 1
Completed
40 enrolled
Washington University School of Medicine
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · collab
Non-randomizedCrossoverSingle-blindTreatment
Summary
An intestinal hormone called Glucose-dependent Insulinotropic Polypeptide (GIP) is released into the blood immediately after ingestion of a meal and plays an important role in regulating blood sugar levels. However, GIP is not active in persons with type 2 diabetes mellitus (T2DM) which is also known as adult onset or non-insulin-dependent diabetes. This study is being conducted to determine whether a hormone called xenin-25 can restore the activity of GIP in persons with T2DM.
Timeline
- Start
- 2008-12
- Primary completion
- 2012-12
- Completion
- 2012-12
Publications
- Results Chowdhury S, Wang S, Patterson BW, Reeds DN, Wice BM. The combination of GIP plus xenin-25 indirectly increases pancreatic polypeptide release in humans with and without type 2 diabetes mellitus. Regul Pept. 2013 Nov 10;187:42-50. doi: 10.1016/j.regpep.2013.10.003. Epub 2013 Oct 29.
- Results Wice BM, Reeds DN, Tran HD, Crimmins DL, Patterson BW, Dunai J, Wallendorf MJ, Ladenson JH, Villareal DT, Polonsky KS. Xenin-25 amplifies GIP-mediated insulin secretion in humans with normal and impaired glucose tolerance but not type 2 diabetes. Diabetes. 2012 Jul;61(7):1793-800. doi: 10.2337/db11-1451. Epub 2012 Apr 20.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Glucose-dependent Insulinotropic Polypeptide | Peptide | 4 unknown | Intravenous |
| Subject | Xenin-25 | Peptide | 4 unknown | Intravenous |